The evaluation and appreciation of the contributions of cohorts
and their role in cancer prevention continues to be debated as the rate
of growth in resources for cancer research slows and future return on
investment becomes an explicit evaluation criterion through assessment
of the impact of proposed studies on public health or clinical programs